Ocuphire Pharma, Inc. (OCUP) |
|
3.65 -0.14 (-3.69%)
|
03-22 15:29 |
|
Open: |
3.76 |
Pre. Close: |
3.79 |
|
High:
|
3.765 |
Low:
|
3.625 |
|
Volume:
|
13,763 |
Market Cap:
|
76(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 3:20:15 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 4.54 One year: 5.3 |
| Support: |
Support1: 3.53 Support2: 3.3 |
| Resistance: |
Resistance1: 3.89 Resistance2: 4.54 |
| Pivot: |
3.68  |
| Moving Average: |
MA(5): 3.76 MA(20): 3.62
MA(100): 3.22 MA(250): 2.63 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 79.8 %D(3): 83.8 |
| RSI: |
RSI(14): 52.8 |
| 52-week: |
High: 4 Low: 1.77 |
| Average Vol(K): |
3-Month: 131 (K) 10-Days: 77 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OCUP ] has closed below upper band by 45.3%. Bollinger Bands are 39.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.83 - 3.85 |
3.85 - 3.87 |
|
Low:
|
3.65 - 3.67 |
3.67 - 3.69 |
|
Close:
|
3.76 - 3.79 |
3.79 - 3.82 |
|
Company Description |
|
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan. |
Headline News |
Tue, 21 Mar 2023
Myopia & Presbyopia Eye Drops Market Report: Analysis of Effective ... - Digital Journal
Mon, 20 Mar 2023
Glaucoma Pipeline Analysis Demonstrates Novel 70+ Companies at ... - Digital Journal
Mon, 20 Mar 2023
Ocuphire Pharma Inc : Profits of 97 cents per share ... - Kalkine Media
Mon, 20 Mar 2023
Soho House & Co Inc Says On March 17, Filed An Amendment To ... - Kalkine Media
Mon, 20 Mar 2023
Golub Capital Bdc Enters Into An Amended And Restated Senior ... - Kalkine Media
Mon, 20 Mar 2023
Cartica Acquisition Corp - Received Written Notice From Cartica ... - Kalkine Media
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
21 (M) |
| Shares Float |
20 (M) |
|
% Held by Insiders
|
4.3 (%) |
|
% Held by Institutions
|
16.4 (%) |
|
Shares Short
|
1,070 (K) |
|
Shares Short P.Month
|
1,050 (K) |
Stock Financials |
|
EPS
|
-5.63 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.19 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-73.3 |
|
Return on Equity (ttm)
|
-137.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.71 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.07 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-20 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
-0.66 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3.11 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-3.84 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-11-05 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
